Read the Latest News

Funding Opportunities now available for the NIH Common Fund’s Acute to Chronic Pain Signatures program

The NIH Common Fund's Acute to Chronic Pain Signatures program aims to understand the biological characteristics underlying the transition from acute to chronic pain and what makes some people susceptible and others resilient to the development of chronic pain.

Opportunity to Voice Your Opinion: U.S. Government Officials Want To Hear from Patients with Pain

FDA Public Meeting on Patient-Focused Drug Development for Chronic Pain On July 9, 2018, FDA hosted a public meeting on Patient-Focused Drug Development for Chronic Pain. https://www.federalregister.gov/documents/2018/05/15/2018-10284/patient-focused-

Consider Including the TMJA in Your Financial Planning

We were recently contacted by Tom P. who informed us that he was including The TMJ Association (TMJA), in his financial planning. Tom wrote the following for us to share with our readers:

The Scoop on TMD Pharmaceuticals

Let's say the National Institutes of Health just handed us a multi-million dollar grant to get to the bottom of TMD and find a cure once and for all. I mean, we could start handing out heating pads left and right, but that kind of relief can only get us so far. Whenever I try a different form of therapy or medication, I like to think about the biology, right down to the cellular and molecular level. Why are the cells that make up my jaw region being such jerks?

Join Us AT TMJ Cafe

The TMJ Association is pleased to partner with Inspire to bring you the TMJ Cafe, a free online support network and discussion community for those with Temporomandibular Disorders (TMD). We invite you to meet others like you, share experiences and tips for getting through the day, and give and receive support.

NIH GRANT OPPORTUNITIES

  • Aug 29, 2018

In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments. The TMJ Association promotes and encourages basic and clinical research on TMD.  We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.

Clinical Coordination Center for Common Fund Acute to Chronic Pain Signatures (A2CPS) Program

  • Posted Date: August 24, 2018
  • Open Date: September 24, 2018
  • Expires: October 25, 2018

The purpose of this FOA is to identify and support a Clinical Coordination Center (CCC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program. The Clinical Coordinating Center is expected to serve as the hub for the Multisite Clinical Centers (below) to support study design, efficiency, progress, and quality, and to coordinate and monitor study implementation across the clinical sites. The Clinical Coordinating Center will lead the consortium in developing and implementing standardized protocols, safety standards, staff training protocols, electronic health record (EHR) data standards, patient phenotyping and testing, and regulatory processes.

 

Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Peri-operative Pain

  • Posted Date: August 24, 2018
  • Open Date: September 24, 2018
  • Expires: October 25, 2018
The purpose of this FOA is to support a Multisite Clinical Center to implement the enrollment and multimodal longitudinal assessment of a large cohort of acute peri-operative pain patients to identify a biosignature for resilience to and the transition from acute to chronic pain.
 
 

Multisite Clinical Center Common Fund Acute to Chronic Pain Signatures Program: Acute Pain from Musculoskeletal Trauma

  • Posted Date: August 24, 2018
  • Open Date: September 24, 2018
  • Expires: October 25, 2018
The purpose of this FOA is to support one Multisite Clinical Center (MCC) to implement the enrollment and multimodal longitudinal assessment of a large cohort of patients with acute pain from a musculoskeletal trauma to identify biosignatures for resilience to and/or the transition from acute to chronic pain.
 
 

Omics Data Generation Centers (ODGCs) for Common Fund Acute to Chronic Pain Signatures Program

  • Posted Date: August 24, 2018
  • Open Date: September 24, 2018
  • Expires: October 25, 2018

The purpose of this FOA is to support the establishment of center(s) that will use cutting edge technologies to perform omics analyses (e.g. metabolomic, lipidomic, proteomic, extracellular RNA) of body fluids collected by the Acute to Chronic Pain Signatures (A2CPS) consortium. The omics data generated, in concert with other patient assessments, will be used to identify biosignatures predictive of susceptibility or resilience to the development of chronic pain.   

 

Data Integration and Resource Center (DIRC) for Common Fund Acute to Chronic Pain Signatures Program

(U54 Clinical Trial Optional) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-18-031.html

  • Posted Date: August 24, 2018
  • Open Date: September 24, 2018
  • Expires: October 25, 2018

The purpose of this FOA is to identify and support a Data Integration and Resource Center (DIRC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program.  The overall programmatic goal of the DIRC is to integrate the efforts of all funded components of the A2CPS and serve as a community-wide nexus for protocols, data, assay and data standards, and other resources generated by the A2CPS Program.

 

Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 & R21 - Clinical Trial Not Allowed)

  • Posted Date: July 25, 2018
  • Open Date: September 16, 2018
  • Expires: September 8, 2021
The purpose of this funding opportunity announcement (FOA) is to encourage research on biologic factors that mediate the differences in prevalence and severity of Dental, Oral, and Craniofacial (DOC)-related diseases and conditions in oral health disparities populations.  It is long recognized that certain racial and ethnic populations suffer an increased burden of DOC diseases and conditions, such as oral/oropharyngeal cancers, early childhood caries (ECC), dental caries, and periodontitis. For each of these diseases, substantial racial and ethnic differences exist in prevalence, severity, persistence and/or disease progression. Biologic factors are believed to play a role in oral health disparities in addition to behavioral, social, and environmental factors. Because critical scientific gaps remain in our understanding of underlying biologic mechanisms that could contribute to these differences, it is difficult to develop targeted therapeutic regimens for those in greatest need.
 
  • Posted Date: July 25, 2018
  • Open Date: September 16, 2018
  • Expires: September 8, 2021

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/ developmental research on biologic factors that mediate the differences in prevalence and severity of Dental, Oral, and Craniofacial (DOC)-related diseases and conditions in oral health disparities populations.  It is long recognized that certain racial and ethnic populations suffer an increased burden of DOC diseases and conditions, such as oral/oropharyngeal cancers, early childhood caries (ECC), dental caries, and periodontitis. For each of these diseases, substantial racial and ethnic differences exist in prevalence, severity, persistence and/or disease progression. Biologic factors are believed to play a role in oral health disparities in addition to behavioral, social, and environmental factors. Because critical scientific gaps remain in our understanding of underlying biologic mechanisms that could contribute to these differences, it is difficult to develop targeted therapeutic regimens for those in greatest need.

 

Expanding the Human Genome Engineering Repertoire

  • Posted Date: July 25, 2018
  • Open Date: September 18, 2018
  • Expires: October 20, 2018

The objective of this Funding Opportunity Announcement is to support research aiming to develop innovative genome editing systems with improved specificity, efficiency, or functionality over currently available systems. Expanding the repertoire of genome editing tools would accelerate the development of novel genome editing therapeutics to treat a broad array of rare and common diseases.

 

Discovery of Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)

(R61/R33) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-18-041.html

  • Posted Date: August 2, 2018
  • Open Date: October 27, 2018
  • Expires: March 13, 2020

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation research using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.

 

Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies

  • Posted Date: August 1, 2018
  • Open Date: September 19, 2018
  • Expires: October 20, 2018

The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness.

Toward these ends, the NIH will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.

 

Clinical Validation of Candidate Biomarkers for Neurological Diseases

  • Posted Date: February 14, 2018
  • Open Date: March 17, 2018
  • Expires: April 17, 2018; July 18, 2018; February, 14, 2019; July 18, 2019; February 14, 2020; and July 20, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of diseases that fall within the mission of NINDS to application in clinical trials and practice (Phase II clinical trials and beyond).
 

 

Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions

 

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-16-295.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PA-16-296.html

  • Posted Date: May 27, 2016
  • Open Date: September 16, 2016
  • Expires: September 8, 2019

The purpose of this funding opportunity announcement (FOA) is to encourage research on mechanisms underlying the manifestations of sex-based differences in Dental, Oral, and Craniofacial (DOC)-related diseases and conditions.  Specifically, this initiative encourages studies aimed at understanding immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes as they affect sex-based differences in DOC-related diseases and conditions including, but not limited to, Sjögren’s Syndrome (SS), orofacial pain, temporomandibular joint (TMJ) disorder (TMD), salivary gland tumors, and human papillomavirus (HPV)-associated oropharyngeal cancers. 

 

NIDCR Small Research Grants for Secondary Analysis of FaceBase Data (R03)

(R03): http://grants.nih.gov/grants/guide/pa-files/PAR-16-362.html

  • Posted Date: July 11, 2016
  • Open Date: September 16, 2016
  • Expires: September 8, 2019

The FaceBase Consortium is developing a variety of comprehensive datasets on craniofacial development that are available to the wider scientific community at www.facebase.org. This funding opportunity announcement (FOA) will support meritorious research projects that conduct secondary data analyses of these FaceBase datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those craniofacial conditions.  Informatics projects that integrate data from multiple FaceBase datasets are especially encouraged. 

 

Tailoring Dental Treatment for Individuals with Systemic Diseases that Compromise Oral Health

(R01): http://grants.nih.gov/grants/guide/pa-files/PAR-16-154.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PAR-16-153.html

  • Posted Date: March 25, 2016
  • Open Date: May 16, 2016
  • Expires: May 8, 2019

This Funding Opportunity Announcement encourages research to address gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. It is expected that research applications will propose studies utilizing established cohorts of individuals with the disease of interest.

 

Personalized Strategies to Manage Symptoms of Chronic Illness

(R15): http://grants.nih.gov/grants/guide/pa-files/PA-16-006.html

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-16-007.html

(R21): http://grants.nih.gov/grants/guide/pa-files/PA-16-008.html

  • Posted Date: October 16, 2015
  • Open Date: January 25, 2016
  • Expires: January 8, 2019

The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. 

 

Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing

(R01): http://grants.nih.gov/grants/guide/pa-files/PA-15-347.html

  • Posted Date: September 17, 2015
  • Open Date: January 5, 2016
  • Expires: January 8, 2019

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality.  Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch.  Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation.  This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs).  The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities.  Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.

 

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System

(UH2/UH3): https://grants.nih.gov/grants/guide/pa-files/PAR-17-205.html

  • Posted Date: March 9, 2017
  • Open Date: July 9, 2017
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions.  Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.

Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.     - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html#sthash.mGoDkIgW.dpuf
The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches. - See more at: http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html#sthash.viviyVB9.dpuf

 

Population Health Interventions: Integrating Individual and Group Level Evidence

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-356.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: May 8, 2019

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

 

Family-Centered Self-Management of Chronic Conditions

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-380.html

(R01):https://grants.nih.gov/grants/guide/pa-files/PA-18-383.html

  • Posted Date: November 21, 2017
  • Open Date: January 16, 2018 / January 5, 2018
  • Expires: January 8, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.

 

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management

(R01): https://grants.nih.gov/grants/guide/pa-files/PA-18-386.html

(R21): https://grants.nih.gov/grants/guide/pa-files/PA-18-389.html

  • Posted Date: November 21, 2017
  • Open Date: January 5, 2018
  • Expires: January 8, 2021

The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. 

The Biomarkers Consortium

The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.

The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.

Information about the Foundation for NIH is available at http://www.fnih.org.

 

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

  • Posted Date: December 21, 2017
  • Open Date: January 7, 2018
  • Expires: May 8, 2020

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program. 

 

This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf
This Notice encourages investigators with expertise and insights into the broad area of Medical Rehabilitation Research sufficient time to develop applications in response to this new FOA. NICHD encourages collaborations among biomedical, behavioral, engineering, and/or psychosocial researchers. Aside from more traditional rehabilitation approaches, NICHD especially encourages support for clinical trial design, applied behavior, engineering and the environment, and personalized medicine in order to promote functional improvement, rehabilitation, and participation for people with disabilities. - See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-HD-14-022.html#sthash.GsPMcpHa.dpuf